SCHEMBL1929307

SCHEMBL1929307

O=C(CO)Nc1ccc(O)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A1 P04798 2/20 0.62
ALDH1A1 P00352 4/20 0.56
MAPT P10636 4/20 0.56
MEN1 O00255 3/20 0.56
KMT2A Q03164 3/20 0.56
PEPD P12955 1/20 0.56
CA12 O43570 1/20 0.56
BRD4 O60885 1/20 0.56
NR1I2 O75469 1/20 0.56
CA1 P00915 1/20 0.56
CA2 P00918 1/20 0.56
MB P02144 1/20 0.56
CA3 P07451 1/20 0.56
CYP3A4 P08684 1/20 0.56
RARG P13631 1/20 0.56
TSHR P16473 1/20 0.56
ALOX5AP P20292 1/20 0.56
CA4 P22748 1/20 0.56
CA7 P43166 1/20 0.56
NR1I3 Q14994 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2352584 0.91 MEN1 (0.56) CYP1A1ALDH1A1MAPTMEN1KMT2A
SCHEMBL27937384 0.84 CYP1A1 (0.84) CYP1A1ALDH1A1MAPTMEN1KMT2A
SCHEMBL8027075 0.81 MEN1 (0.53) CYP1A1ALDH1A1MAPTMEN1KMT2A
SCHEMBL3659521 0.80 CA1 (0.61) CYP1A1ALDH1A1MAPTMEN1KMT2A
SCHEMBL6832724 0.80 CYP1A1 (0.71) CYP1A1ALDH1A1MAPTMEN1KMT2A
Parapropamol SCHEMBL1064972 0.80 MAPT (0.63) CYP1A1ALDH1A1MAPTMEN1KMT2A
SCHEMBL16569266 0.80 POLB (0.47) MEN1KMT2ACA12CA1CA2
SCHEMBL2635734 0.80 NPC1 (0.66) CYP1A1ALDH1A1MAPTMEN1KMT2A
SCHEMBL1134070 0.80 CYP1A1 (0.60) CYP1A1ALDH1A1MAPTMEN1KMT2A
SCHEMBL6794740 0.80 GAA (0.66) ALDH1A1MEN1KMT2AGAAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE45548-E1 Functionalized drugs and polymers derived therefrom BEZWADA BIOMEDICAL, LLC (US) 2015-06-09 US disclosed
US-RE45548-E1 Functionalized drugs and polymers derived therefrom BEZWADA BIOMEDICAL, LLC (US) 2015-06-09 US disclosed
US-RE45548-E1 Functionalized drugs and polymers derived therefrom BEZWADA BIOMEDICAL, LLC (US) 2015-06-09 US disclosed
US-8409559-B2 Functionalized drugs and polymers derived therefrom Bezwada Biomedical, Inc. (US) 2013-04-02 US disclosed
US-8409559-B2 Functionalized drugs and polymers derived therefrom Bezwada Biomedical, Inc. (US) 2013-04-02 US disclosed
US-8409559-B2 Functionalized drugs and polymers derived therefrom Bezwada Biomedical, Inc. (US) 2013-04-02 US disclosed
US-8372882-B2 Functionalized phenolic esters and amides and polymers therefrom BEZWADA BIOMEDICAL, LLC (US) 2013-02-12 US disclosed
US-8372882-B2 Functionalized phenolic esters and amides and polymers therefrom BEZWADA BIOMEDICAL, LLC (US) 2013-02-12 US disclosed
US-8372882-B2 Functionalized phenolic esters and amides and polymers therefrom BEZWADA BIOMEDICAL, LLC (US) 2013-02-12 US disclosed
US-8198458-B2 Non-nucleoside reverse transcriptase inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-06-12 US disclosed
US-20100152272-A1 FUNCTIONALIZED DRUGS AND POLYMERS THEREFROM BEZWADA BIOMEDICAL, LLC (US) 2010-06-17 US disclosed
US-7691364-B2 Functionalized drugs and polymers derived therefrom BEZWADA BIOMEDICAL, LLC (US) 2010-04-06 US disclosed
US-7691364-B2 Functionalized drugs and polymers derived therefrom BEZWADA BIOMEDICAL, LLC (US) 2010-04-06 US disclosed
US-7691364-B2 Functionalized drugs and polymers derived therefrom BEZWADA BIOMEDICAL, LLC (US) 2010-04-06 US disclosed
US-7517998-B2 Benzothiazole or benzothiazine derivative of dipyrido(2,3;b:2',3'-e) diazepin-6-one; viricide against human t-cell leukemia/lymphoma virus BOEHRINGER INGELHEIM INTERNATIONAL GMBH 2009-04-14 US disclosed
EP-1931334-A2 FUNCTIONALIZED DRUGS AND POLYMERS DERIVED THEREFROM Bezwada Biomedical LLC (US) 2008-06-18 EP disclosed
WO-2007030538-A2 FUNCTIONALIZED DRUGS AND POLYMERS DERIVED THEREFROM BEZWADA BIOMEDICAL LLC (US) 2007-03-15 WO disclosed
WO-2007030538-A2 FUNCTIONALIZED DRUGS AND POLYMERS DERIVED THEREFROM BEZWADA BIOMEDICAL LLC (US) 2007-03-15 WO disclosed
US-20060172983-A1 Functionalized drugs and polymers derived therefrom BEZWADA BIOMEDICAL, LLC (US) 2006-08-03 US disclosed
US-20060173065-A1 Functionalized phenolic esters and amides and polymers therefrom BEZWADA BIOMEDICAL LLC 2006-08-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152272-A1 FUNCTIONALIZED DRUGS AND POLYMERS THEREFROM OGFR, LOX, DDO CYP1A1 2514/4885ALDH1A1 891/4885MAPT 923/4885
US-20060172983-A1 Functionalized drugs and polymers derived therefrom OGFR, LOX, OPRM1 CYP1A1 2799/4885ALDH1A1 972/4885MAPT 579/4885
US-20060173065-A1 Functionalized phenolic esters and amides and polymers therefrom HAAO, HAO2, HCAR3 CYP1A1 1165/4885ALDH1A1 132/4885MAPT 3480/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.